EU set to launch full-scale investigation into Grail-Illumina deal amid antitrust concerns — report
The proposed $8 billion merger between liquid biopsy firm Grail and cancer blood screening giant Illumina has met with nothing but flack since it was first announced in September. After hitting waves in the US earlier this year, the pact is now facing a potentially devastating setback in the EU as well.
The EU is prepared to launch a full-scale probe into a pending merger between Grail and Illumina that has evolved into Exhibit A for international antitrust advocates’ case against noncompetitive pharma M&A, sources close to the deal told Reuters.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.